TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

BRISDELLE

PAROXETINE MESYLATE
Neurology Approved 2013-06-28
1
Indication
--
Phase 3 Trials
12
Years on Market

Details

Status
Prescription
First Approved
2013-06-28
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: PAROXETINE MESYLATE

BRISDELLE Approval History

Loading approval history...

What BRISDELLE Treats

2 indications

BRISDELLE is approved for 2 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Vasomotor Symptoms
  • Menopause
Source: FDA Label

BRISDELLE Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS Selective serotonin reuptake inhibitors (SSRIs) increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term trials for the treatment of major depressive disorder and other psychiatric disorders. Because BRISDELLE is an SSRI, closely monitor BRISDELLE-treated patients closely for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . BRISDELLE is not approved for use in any psychiatric cond...

Drugs Similar to BRISDELLE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

LYNKUET
ELINZANETANT
2 shared
Bayer
Shared indications:
Vasomotor SymptomsMenopause
ACTIVELLA
ESTRADIOL
1 shared
Novo Nordisk
Shared indications:
Vasomotor Symptoms
ANGELIQ
DROSPIRENONE
1 shared
Bayer
Shared indications:
Vasomotor Symptoms
BIJUVA
ESTRADIOL
1 shared
MAYNE PHARMA
Shared indications:
Vasomotor Symptoms
CLIMARA
ESTRADIOL
1 shared
Bayer
Shared indications:
Vasomotor Symptoms
CLIMARA PRO
ESTRADIOL
1 shared
BERLEX LABS
Shared indications:
Vasomotor Symptoms
CONJUGATED ESTROGENS
ESTROGENS, CONJUGATED
1 shared
NOVAST LABS
Shared indications:
Vasomotor Symptoms
DIVIGEL
ESTRADIOL
1 shared
VERTICAL PHARMS
Shared indications:
Vasomotor Symptoms
DUAVEE
BAZEDOXIFENE ACETATE
1 shared
Pfizer
Shared indications:
Vasomotor Symptoms
ELESTRIN
ESTRADIOL
1 shared
Viatris
Shared indications:
Vasomotor Symptoms
ESTRADIOL
ESTRADIOL
1 shared
Viatris
Shared indications:
Vasomotor Symptoms
ESTRADIOL AND NORETHINDRONE ACETATE
ESTRADIOL
1 shared
Teva
Shared indications:
Vasomotor Symptoms
ESTRADIOL VALERATE
ESTRADIOL VALERATE
1 shared
Hikma
Shared indications:
Vasomotor Symptoms
ESTROGEL
ESTRADIOL
1 shared
ASCEND THERAPS US
Shared indications:
Vasomotor Symptoms
EVAMIST
ESTRADIOL
1 shared
PADAGIS US
Shared indications:
Vasomotor Symptoms
FEMRING
ESTRADIOL ACETATE
1 shared
MILLICENT MFG PR
Shared indications:
Vasomotor Symptoms
FYAVOLV
ETHINYL ESTRADIOL
1 shared
Lupin
Shared indications:
Vasomotor Symptoms
MINIVELLE
ESTRADIOL
1 shared
NOVEN
Shared indications:
Vasomotor Symptoms
PREMPHASE 14/14
ESTROGENS, CONJUGATED
1 shared
Pfizer
Shared indications:
Vasomotor Symptoms
PREMPRO
ESTROGENS, CONJUGATED
1 shared
Pfizer
Shared indications:
Vasomotor Symptoms
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BRISDELLE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Limitations of Use: BRISDELLE is not indicated for the treatment of any psychiatric condition. BRISDELLE has a lower recommended paroxetine dosage than that used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and effectiveness of the lower BRISDELLE dosage has not been established for any psychiatric condition. Patients who require paroxetine fo...

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Selective serotonin reuptake inhibitors (SSRIs) increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term trials for the treatment of major depressive disorder and other psychiatric disorders. Because BRISDELLE i...

BRISDELLE Patents & Exclusivity

Latest Patent: Apr 2029

Patents (3 active)

US8658663 Expires Apr 6, 2029
US8946251 Expires Aug 4, 2026
US9393237 Expires Aug 4, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.